Mohammad Vaseemuddin, MD
Internal Medicine · Addison, ILNPI 1952453995
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,506 of the $5,425 with a category attached, or 64.6%. Otsuka America Pharmaceutical, Inc. accounts for 88.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $4,777 and has fallen 96.0% since, to $191 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $169.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$5K
- AbbVie$125
- Calliditas Therapeutics US Inc.$123
- Lilly USA, LLC$91
- Bayer$64
- AstraZeneca$46
- plus $195 from 7 others
What the payments were for
- Consulting fees$3,50665%
- Travel & lodging$1,03419%
- Food & beverage$88616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $4,782 |
| AbbVie | 1 | $125 |
| Calliditas Therapeutics US Inc. | 7 | $123 |
| Lilly USA, LLC | 1 | $91 |
| Bayer | 3 | $64 |
| AstraZeneca | 3 | $46 |
| Amgen | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Exact Sciences | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$125
How this compares
$5,425 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 95 | $144,107 |
| FarxigaDapagliflozin Propanediol | 61 | $64,012 |
| KerendiaFinerenone | 35 | $54,207 |
| TrulicityDulaglutide | 22 | $24,336 |
| JardianceEmpagliflozin | 14 | $19,601 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $974 |
| Dutasteride | 13 | $936 |
| Potassium Chloride | 30 | $605 |
| Atorvastatin Calcium | 69 | $586 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $508 |
| Rosuvastatin Calcium | 19 | $423 |
| Lisinopril | 52 | $404 |
| Tamsulosin Hcl | 31 | $366 |
| Pantoprazole Sodium | 48 | $358 |
| Amlodipine Besylate | 52 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $91 | $168,443117 claims |
| AstraZenecaFarxiga | $46 | $64,01261 claims |
| BayerKerendia | $64 | $54,20735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Addison
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
- Peter O DonnellChicago$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.